A new vaccine to improve tuberculosis prevention

A STINGing vaccine for TB

NIH-funded research Johns Hopkins University · NIH-10841675

This study is testing a new version of the BCG vaccine to see if it can better protect against tuberculosis and possibly help treat bladder cancer, and they’re looking for patients to join the trials to help find out how safe and effective it is.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionJohns Hopkins University NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-10841675 on NIH RePORTER

What this research studies

This research focuses on developing a modified version of the Bacille Calmette–Guérin (BCG) vaccine to enhance its effectiveness against tuberculosis (TB). The new vaccine, called BCG-disA-OE, is engineered to stimulate a stronger immune response and has shown promising results in animal models. By administering this vaccine through different routes, the researchers aim to improve protection against TB and also explore its potential use in treating non-muscle invasive bladder cancer. Patients may be involved in trials to assess the vaccine's safety and efficacy.

Who could benefit from this research

Good fit: Ideal candidates for participation would include adults over 21 years old who are at risk for tuberculosis or have non-muscle invasive bladder cancer.

Not a fit: Patients who are not at risk for tuberculosis or do not have bladder cancer may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to a more effective vaccine that significantly reduces the incidence of tuberculosis and improves treatment options for bladder cancer.

How similar studies have performed: Other studies have shown promise in modifying BCG for improved efficacy, indicating that this approach has potential based on previous research.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions communicable disease control agent
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.